ATLASATLAS fair value
₹1,276
Close to fair value · 1% discount
Range: ₹1,149–₹1,404Fair valuePrice
Alivus Life Sciences (GLS.NSE)
Alivus Life Sciences share price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · National Stock Exchange of India · India
₹1,262▲ +0.91%
Prices as of Oct 26, 2026 · INR
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Alivus Life Sciences in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Alivus Life Sciences
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Alivus Life Sciences's fair value at about ₹1,276 per share (reasonable range: ₹1,149 to ₹1,404). At ₹1,262, the stock trades within 8% of that figure: close to fair value.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Alivus Life Sciences a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₹1,188 and ₹1,342; in 9 out of 10, between ₹1,066 and ₹1,496. Estimated annual volatility is 35%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₹155B
- Market cap (USD)
- $1.6B
- P/E ratio
- 31.5
- Dividend yield
- 3.56%
- 52-week high
- ₹1,494
- 52-week low
- ₹819.00
- Revenue (12 months)
- ₹21.8B
- Operating margin
- 29.0%
- Net margin
- 53.3%
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Alivus Life Sciences sits close to fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks GLS.NSE has traded between ₹819.00 and ₹1,494. Today it is 15.5% below that high and 54% above its low.
On the business: net margin is 53.3%; it trades at 31.5 times earnings.
About the company
Alivus Life Sciences Ltd. is a pivotal player in the biotechnology and pharmaceutical industries, focusing on the research, development, and commercialization of innovative healthcare solutions.
Want to see everything about Alivus Life Sciences?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Alivus Life Sciences (GLS.NSE) fair value?
About ₹1,276 per share according to ATLAS (reasonable range: ₹1,149 to ₹1,404). With the stock at ₹1,262, it is close to that value.
What is the chance GLS.NSE goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, GLS.NSE ends the month between ₹1,188 and ₹1,342.
How big is Alivus Life Sciences and what is its P/E ratio?
Alivus Life Sciences's market capitalization is ₹155B. Its price-to-earnings (P/E) ratio is 31.5: you pay ₹31.5 for each ₹1.00 of yearly earnings.
Does Alivus Life Sciences pay a dividend?
Yes. GLS.NSE's current dividend yield is 3.56% at today's price (₹1,262).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer